It has been proposed that human tumors contain stem cells that have a central role in tumor initiation and posttreatment relapse. Putative breast cancer stem cells may reside in the CD44 + CD24
Introduction
Decades ago, it was proposed that aberrant stem cells might underlie the heterogeneous nature of many advanced tumors. However, it is only recently that this theory has gained support from molecular evidence. Nonetheless, because cancer stem cells have not yet been fully defined, it cannot conclusively be proven that they exist, and there are also competitive hypotheses (reversible epidermal to mesenchymal transition, mutator phenotypes, etc.), which might explain some of the puzzling features of certain tumor cell populations. With regard to breast cancer, the cancer stem cell hypothesis is supported by the finding that CD44 + CD24
À/low cells, frequently found in primary tumors and metastases, exhibit stem cell characteristics, including self-renewal and differentiation along various mammary epithelial lineages (1) (2) (3) . A low number of CD44 + CD24 À/low cells, as opposed to unsorted cells, is sufficient for initiation of tumors in mice (4) . Because of slow turnover and the ability for expelling antitumor drugs, putative cancer stem cells are resistant to many conventional cancer therapies (5) . Therefore, they may have an important role in relapse after treatment and might therefore be causative of the incurable nature of many advanced solid tumors including metastatic breast cancer. Because most antitumor agents have been approved based on tumor response, agents preferentially active on cancer stem cells (which form a minority of the bulk of the tumor) may have been missed.
Viruses capable of selectively killing tumor cells, including oncolytic adenoviruses, enter cells through infection and kill both proliferating and quiescent cells. Such viruses are rendered replication deficient in normal cells by engineered genetic changes that are transcomplemented in tumor cells. One useful approach in this regard is utilization of tissue or tumor-specific promoters (TSP), which are activated in target cells, whereas nontumor cells are spared (6) .
As there are no previous reports on which promoters might be useful in the context of cancer stem cells, we constructed viruses featuring the a-lactalbumin (ala; ref. 7), cyclo-oxygenase 2 (Cox-2; ref. 8) , telomerase (hTERT; ref. 9) , and multidrug resistance (mdr; ref. 10) promoters. Given that many stem cell types express low levels of the rate-limiting coxsackie-adenovirus receptor (11) (12) (13) (14) , we studied the utility of viral capsid modification for enhanced delivery. Then, we constructed the respective capsid modified, promoter-controlled oncolytic adenoviruses, and investigated their utility for killing CD44 + CD24 À/low breast tumor cells in vitro and in vivo.
Materials and Methods
Cells. Pleural effusions were obtained with ethics committee-approved informed consent and washed with DMEM/F12 supplemented with 10ng/mL basic fibroblast growth factor, 20 ng/mL epidermal growth factor, 5 Ag/mL insulin, and 0.4% bovine serum albumin (all from Sigma). All three patients ( Fig. 2A -C corresponds to patients PL11-13) had metastatic ductal breast cancer. PL11: 58 y, grade 1, ER+, PR+, Her2À (CISH); PL12: 59 y, grade 3, ER+, PRÀ, Her2À. PL13: 85 y, grade 3, ER+, PR+, Her2À. JIMT-1 cells were cultured as reported (15) . Cells were sorted with FITC-labeled anti-CD44 and phycoerythrin-labeled anti-CD24 antibodies (BD PharMingen), collected with magnetic beads (Miltenyi Biotech). Cells (911, 293, and A549) are from American Type Culture Collection (ATCC).
Viruses. Ad5/3ala-d24, Ad5/3mdr-E1, and Ad5/3mdr-d24 were constructed by cutting promoter sequences from pGL3-ALA (7) and pM3mdr-p-hTNF (10) into pSE1 and pSE1d24 (16) , from which the E1 promoter was removed. The viral backbone was rescued in 911 cells with PacI-digested pTU-5/3 (17) . For construction of Ad5/3-hTERT-Dgp, the hTERT was cloned into pSE1 (16) , resulting in pShTERTE1. pAd5/ 3-hTERT-E1-Dgp was generated by homologous recombination in BJ5183 cells using PmeI-digested pShTERTE1 and SrfI-linearized pAdEasy-1.5/ 3-Dgp (serotype 3 knob, a 24-bp deletion in E1A and a 965-bp 6.7K/gp19K deletion in E3A) for transfection into 911 cells. Propagation of these viruses and of Ad5/3-d24 (14) and Ad5/3-Cox2L-D24 (12) was performed on A549 cells.
The same promoter sequences were cloned to replace cytomegalovirus (CMV) in pShuttle-CMV (AdEasy; QBiogene) and luciferase was cut from pGL3-Basic (Promega) for homologous recombination with pAdEasy. Wildtype adenovirus (Ad5wt) is from ATCC. Ad5luc1, Ad5lucRGD, and Ad5/ 3luc1 have been reported (12, 13) . E1-deleted viruses were propagated on 293 cells (Microbix). All viruses were purified on double CsCl gradients using standard methods. The E1 and E3 regions, fiber, and TSPs were checked with PCR followed by sequencing (11, 16) . The viruses were titered for viral particles (VP) at 260 nm. Functional titer was determined with plaque assay with an initial overnight infection of 293 cells.
Luciferase assay. Cell lines were plated, infected the next day, and washed once. After 24 h, the medium was removed, cells were lysed with 200 AL of Reporter lysis buffer (Promega), and freeze thawed once followed by luciferase assay (Reporter Lysis Buffer; Promega). Standardization was accomplished by comparing to CMV (set as 100%).
Gene expression analysis. Oncolysis assay. Cell lines were infected for 1 h and incubated in medium with 5% fetal bovine serum, half of which was changed every other day. Cells were checked daily and when the most oncolytic virus seemed to have killed most of the cells at 1 VP per cell, MTS assay (CellTiter96 Aqueous One Solution Reagent; Promega) was performed.
In vivo analyses. Sorted JIMT-1 cells (2 Â 10 6 ) were injected into the topmost mammary fat pads of nude mice (18) . Mice were injected with 1 mg/kg Estradurin (Pfizer) every 3 wk as reported (1) . Intratumoral injections were performed with 10 9 VP thrice weekly for 5 wk. Tumor volume = length Â width 2 Â 0.5. Animal experiments were approved by the Provincial Government of Southern Finland.
Flow cytometry. Expression of CD44 and CD24 in tumors (n = 7 per group) was measured by flow cytometry after 17 d of treatment. Briefly, tumors were dissociated with collagenase (Blend type F; Sigma) overnight in +4jC. Cells (2 Â 10 6 ) from each tumor were labeled with antibodies as above and samples were analyzed with FACSaria (Becton Dickinson).
Statistical analysis. The F-test was performed to see if there were differences between the oncolytic potency of the viruses in vitro. If there was unequal distribution of the results, a two-sided Student's t test was used to assess significance, defined as a two-sided value of P < 0.05. In vivo, a nonparametric change-point test was used to determine a systematic change in the pattern of observations as opposed to chance. Proc Mixed (SAS v.6.12; SAS Institute) was used to examine the effects of group and time on tumor growth. Pairwise comparisons were performed.
Results
Breast cancer cells were sorted for CD44 and CD24 and infected by viruses featuring TSPs (Fig. 1A) . Mdr showed the strongest activity with 17.8% or 6% of the highly active but nonselective CMV promoter, respectively, in JIMT-1 and fresh patient cells. hTERT also gave high activity at 3.1% and 12.8% of CMV, whereas Cox-2 was also active at 5.2% and 7.9%, respectively. Expression levels of ala were 0.4% and 1.8% of CMV and seem too low for successful control of oncolytic adenoviruses. RT-PCR analysis confirmed expression of genes that showed high luciferase expression (Fig. 1A, insert) . However, correlation was not perfect between the assays suggesting that factors other than promoter activity may play a role in mRNA expression (e.g., mRNA stability factors present in untranslated regions).
For comparison, CD24+ JIMT-1 cells were analyzed for TSP expression (Fig. 1A, center) . The main difference was that mdr was expressed to lower and ala to higher degree than in the CD44 + CD24
À/low population.
Capsid modified luciferase expressing viruses were used to investigate if gene transfer to CD44 + CD24 À/low or CD24+ cells could be improved (Fig. 1B) . 5/3 modification seemed the optimal capsid configuration as it achieved 10-and 100-fold higher gene transfer to CD44 + CD24 À/low and CD24+ cells, respectively. These results prompted us to construct the respective oncolytic adenoviruses featuring the respective TSPs and incorporating the 5/3 capsid (Fig. 1C) . In many cases, an Rb binding site deletion was included as our previous data suggests that this can improve selectivity without loss of efficacy (12) . When CD44 + CD24 À/low cells fresh from pleural effusions were infected, we found that 5 of 3 modified viruses were more oncolytic than the wild-type Ad5 control (Fig. 2) . In 2 of 3 samples, Ad5/ 3-mdr-D24 was most oncolytic, with Ad5/3-hTERT-Dgp and Ad5/ 3-Cox2L-D24 closely following. Impressively, despite including a TSP, these viruses were sometimes even more potent than the highly active Ad5/3-D24. Adding the Rb binding site deletion to Ad5/3-mdr-E1A to make Ad5/3-mdr-D24 did not reduce the activity of the virus but actually increased potency. As expected from the luciferase data, the ala promoter-driven oncolytic virus did not show oncolytic activity. CD44 + CD24 À/low cells fresh from pleural effusions did not propagate actively in vitro, which may support their ''stemness''. Nevertheless, this precluded analysis of all viruses on all samples. For experiments that required large numbers of cells, the JIMT-1 explant was used (Figs. 3-4) . To look at the kinetics of cell killing between the different viruses, JIMT-1 cells were infected and daily cell viability assays were performed (Fig. 3A) . Ad5/3-mdr-D24 and Ad5/3-hTERT-Dgp were the most effective TSP viruses and similar in the efficacy with the highly active Ad5/3D24, included as a positive control. Because probably not all CD44 + CD24 À/low cells are ''stem'' cells (progenitors may be included), it is important to note that viruses were able to kill 100% of cells, therefore including also the actual ''cancer stem cells.'' As an alternative method for analyzing cell killing, trypan blue assays were performed as a function of time ( 3-mdr-D24-treated tumors, 50% of the section was necrotic and also non-necrotic regions displayed condensed nuclei, suggesting initiation of cell death (data not shown).
To assess antitumor efficacy, CD44 + CD24 À/low -derived tumors were established and injected with oncolytic viruses, all of which resulted in significantly smaller tumor size versus mock (all P < 0.001; Fig. 4A ). Ad5/3cox2LD24 and Ad5/3-mdr-D24 showed the greatest antitumor efficacy and Ad5/3-mdr-D24 was superior even to Ad5/3-D24, a highly active positive control (P < 0.001). Interestingly, despite promising activity in vitro, Ad5/3-hTERT-Dgp was less effective in vivo than Ad5/3-D24 (P < 0.001).
Putative stem cells would be predicted to divide asymmetrically; each division producing one new stem cell and one progenitor. Progenitors would then divide to produce differentiated tumor cells. To assess this in a preliminary manner, tumors were induced by injection of 100% CD44 + CD24
À/low cells, and the proportion CD44 + CD24 À/low cell was analyzed again when mice died or were killed. In mock-injected tumors, the proportion of CD44 + CD24 À/low cells had decreased from 100% to 6.2% (n = 2; SD, 6.8). In Ad5/ 3cox2L-D24-injected tumors, the proportion reduced to 1.2% (n = 1), whereas in Ad5/3mdr-D24, Ad5/3-D24, and Ad5/ 3-hTERT-Dgp-injected tumors, the respective numbers were 3.8% + CD24 low/À and CD24 + JIMT-1 cells were infected with 500 VP per cell of Ad5, a virus featuring serotype 5/3 chimeric capsid or a RGD-4C modified capsid. Twenty-four hours after infection, cells were lysed and luciferase activity was determined and normalized to the cellular protein content. Columns, mean; bars, SE. C, oncolytic adenoviruses featuring the TSPs and 5/3 modification of the capsid were constructed. All viruses have intact E3 except for Ad5/3-hTERT-Dgp, which is deleted for gp19K . For additional tumor selectivity, D24 viruses have a 24-bp deletion in the constant region 2 of E1A, which renders them unable to bind Rb, and therefore, these viruses replicate selectively in p16-Rb pathway-deficient cells.
Promoters Active in Cancer Stem Cells www.aacrjournals.org (n = 3; SD, 3.5), 1.2% (n = 3; SD, 0.4), and 1.6% (n = 1). The absolute number of CD44 + CD24
À/low cells decreased from 2 million to a median of 669,000 (n = 8; SD, 1.2 million) in virus-injected tumors. However, because the number of tumors available for analysis was limited by practical aspects (duration of analysis and freshness of tumor), and the time points of analysis were not standardized in the efficacy experiment, we performed another set of experiments in more rigorous conditions (Fig. 4B and C) . Tumors were established and treated with mock, Ad5/3mdr-D24 (able to kill CD44+/CD24À cells in vitro; Figs. 2-3) , or Ad5/3-ala-D24 (not able to kill CD44+/CD24À cells in vitro) for 17 days, followed by fluorescence-activated cell sorting (FACS; Fig. 4B and C ) . Interestingly, the proportion of CD44 + CD24
À/low cells was nearly identical [3.1% (SD, 1.35) versus 2.6% (SD, 1.17) in Ad5/3mdr-D24 Figure 2 . Primary breast cancer pleural effusion samples from 3 different patients (A-C ) were sorted for CD24-negative and CD44-positive cells and seeded at 20,000 cells per well on 96-well plates. After infection with promoter-driven oncolytic viruses, cells were checked daily by light microscopy, and MTS cell viability assay was performed when the most potent virus had lysed virtually all cells with the second lowest viral concentration. Results are presented as relative survival compared with mock-infected cells. Points, mean; bars, SE. ***, P < 0.001 versus Ad5wt.
versus mock-treated groups, and 3.3% (SD, 0.27) versus 3.4% (SD, 0.53) in Ad5/3-ala-D24 versus mock-treated groups, respectively; Fig. 4C ]. Importantly, because Ad5/3mdr-D24 reduced tumor size, it also reduced the total number of CD44+/CD24-cells (Fig. 4A-C) . In contrast, Ad5/3-ala-D24 did not affect tumor size nor the proportion of CD44+/CD24À (Fig. 4B and C) . In mock versus Ad5/3mdr-D24-treated groups, other cell populations had larger differences: 5.4% (SD, 4.72) versus 2.3% (SD, 0.97), 9.2% (SD, 6.75) versus 4.3% (SD, 1.37), 82.3% (SD, 11.3 
Discussion
Previous work suggests that cancer stem cells may underlie the relapsing nature of advanced cancer (1) (2) (3) (4) . Eradication of these cells seems daunting as they are resistant to chemotherapy and radiation (5) . Nevertheless, oncolytic viruses may have potential in this regard, as they are not susceptible to ion pumps or lack of cell cycling. Although oncolytic adenoviruses have been quite safe in the dozens of trials, most of them have been performed with relatively attenuated early generation agents (19) . A new generation of infectivity enhanced, armed, and highly effective viruses is rapidly emerging, and the first such viruses have already been tested in patients with good safety. 9 Nevertheless, preclinical data suggests that enhanced potency can sometimes result in toxicity, and therefore, improved control of virus replication may become clinically relevant (20) .
TSPs may be a useful way to prevent expression of adenoviral E1A in nontarget tissues (6, 12, 16) . Dual control may be particularly useful in the context of nontumor cells positive for the TSP. For example, normal tissue stem cells might express hTERT or mdr. Nevertheless, they would be expected to be intact in the Rb-p16 pathway, and therefore, D24-type viruses should not replicate in them.
Given the paucity of TSPs known to be active in putative cancer stem cells, we focused on a handful of promoters theoretically useful. Luciferase assays indicated that all of these promoters, except ala, were active in CD44 + CD24 À/low cells. 5/3 chimerism was identified as the optimal capsid configuration, and oncolytic viruses were subsequently constructed (Fig. 1) . The respective viruses were effective in killing CD44 + CD24 À/low cells (Figs. 2-3 ).
However, in the most stringent assay (Fig. 4) , Ad5/3-mdr-D24 and Ad5/3-Cox2L-D24 emerged as the most promising agents, with Ad5/3-mdr-D24 perhaps holding the advantage given slightly superior data on clinical specimens (Fig. 2) . Nevertheless, Ad5/ 3-Cox2L-D24 also had activity in clinical samples, especially at lower doses, which may be promising with regard to in vivo application. Importantly, in vivo data suggested that asymmetrical cell division does occur. and Ad5/3-Cox2L-D24 may be appealing for testing in breast cancer patients.
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